TMX Newsfile·2026-03-18 02:29Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from June 5, 2023, to December 26, 2025 [1]. Group 1: Class Action Details - Investors who purchased Mereo ADSs during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements [4]. Group 3: Case Background - The lawsuit claims that Mereo BioPharma provided investors with misleading information regarding the expected results of their Phase 3 studies for setrusumab in Osteogenesis Imperfecta (OI), which ultimately did not meet their primary endpoints [5][6]. - The misleading statements led to investors purchasing Mereo's ADSs at artificially inflated prices, resulting in damages when the true information was revealed [6].